Provided by Tiger Trade Technology Pte. Ltd.

T. Rowe Price Health Care ETF

33.22
-0.1186-0.36%
Post-market: 33.19-0.0277-0.08%16:16 EDT
Volume:3K
Turnover:85.60K
Market Cap:32.39M
PE:- -
High:33.32
Open:33.32
Low:33.08
Close:33.34
52wk High:36.72
52wk Low:27.57
Shares:975.00K
Float Shares:975.00K
Volume Ratio:0.35
T/O Rate:0.26%
Dividend:0.16
Dividend Rate:0.49%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Agilent Technologies Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 01

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Gilead Sciences Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Moderna Inc. Stock Sheds 5.4%, Underperforms Peers

Dow Jones
·
Oct 01

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
Oct 01

Gilead put volume heavy and directionally bearish

TIPRANKS
·
Oct 01

Judge Denies In Part UnitedHealth's Motion to Dismiss CalPERS Suit

MT Newswires Live
·
Oct 01

Judge Denies in Part UnitedHealth's Motion to Dismiss CalPERS Suit

MT Newswires Live
·
Oct 01

Sector Update: Healthcare

MT Newswires Live
·
Oct 01

Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

TIPRANKS
·
Oct 01

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Sep 30

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30